Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa

Related Keywords

United Kingdom ,Seoul ,Soult Ukpyolsi ,South Korea ,Japan ,Cambridge ,Cambridgeshire ,London ,City Of ,Tokyo ,Frazer Hall ,Shinichiro Nishishita ,Bristi Basu ,Hironoshin Nomura ,Maya Bennison ,Sosei Heptare ,Nigel Blackburn ,Sosei Heptares ,Debashis Sarker ,Matt Barnes ,United Kingdom At Cambridge University Hospitals ,Sosei Group ,Youtube ,University Of Cambridge ,Facebook ,Sosei Group Corporation The Company ,Cancer Research United Kingdom ,Linkedin ,Tokyo Stock Exchange ,Experimental Cancer Medicine Centre ,Twitter ,Medistrava Consulting For International Media ,Sosei Group Corporation ,Regulatory Agency ,King College London ,Research United Kingdom ,Drug Development ,Co Chief Investigator ,College London ,Cambridge University Hospitals ,Heptares Therapeutics ,United Kingdom Medicines ,Innovation Passport ,Licensing Access Pathway ,Innovation Passports ,Clinical Trial ,Licence Agreement ,Cancer Research United Kingdom Centre ,Chief Financial Officer ,International Media ,Cancer Research Uk ,Cancer Research ,Uk ,Sosei ,Ancer Immunotherapy ,Prostate Cancer ,Development ,Hase Ii Studies ,